Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 2,500 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,500 shares of the firm’s stock in a transaction dated Thursday, July 23rd. The shares were bought at an average price of $13.14 per share, with a total value of $32,850.00. Following the purchase, the chief executive officer owned 5,606,602 shares in the company, valued at $73,670,750.28. The trade was a 0.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Friday, July 24th, Snehal Patel purchased 1,100 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $12.88 per share, for a total transaction of $14,168.00.

Greenwich LifeSciences Trading Up 0.1%

Greenwich LifeSciences stock opened at $13.45 on Wednesday. Greenwich LifeSciences, Inc. has a 12 month low of $7.78 and a 12 month high of $34.10. The business’s 50 day simple moving average is $21.63 and its 200 day simple moving average is $24.26. The company has a market cap of $197.45 million, a price-to-earnings ratio of -8.57 and a beta of 1.40.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GLSI. Wall Street Zen cut Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. HC Wainwright lifted their price objective on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $57.00.

Institutional Trading of Greenwich LifeSciences

A number of institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares during the period. Rhumbline Advisers raised its holdings in Greenwich LifeSciences by 48.7% during the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after acquiring an additional 3,168 shares during the period. Wells Fargo & Company MN raised its holdings in Greenwich LifeSciences by 109.6% during the 4th quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after acquiring an additional 4,102 shares during the period. Strs Ohio purchased a new stake in shares of Greenwich LifeSciences during the first quarter worth $177,000. Finally, Jane Street Group LLC purchased a new stake in shares of Greenwich LifeSciences during the fourth quarter worth $203,000. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.